{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.96","upperLimit":"52.64","value":"45.80"},{"groupId":"OG001","lowerLimit":"34.36","upperLimit":"43.20","value":"37.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"446"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"description":"OS defined as the time from the date of randomization to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive. The final analysis of the OS outcome was conducted after 440 OS events had been observed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Abemaciclib 150 mg administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG000","title":"Abemaciclib + Fulvestrant"},{"description":"Placebo administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG001","title":"Placebo + Fulvestrant"}],"paramType":"MEDIAN","populationDescription":"All randomized participants. Censored participants: Abemaciclib=163 (36.5%), Placebo = 66 (29.6).","reportingStatus":"POSTED","timeFrame":"From Date of Randomization until Death Due to Any Cause (Up To 72 Months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}